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Autoimmune disease occurs when the immune system attacks self-molecules as a result of a
breakdown of immunologic tolerance to autoreactive immune cells. Many autoimmune disorders
have been strongly associated with genetic, infectious, and/or environmental predisposing factors.
Comprising multiple disorders and symptoms ranging from organ-specific to systemic, autoimmune
diseases include insulin-dependent diabetes mellitus, rheumatoid arthritis, systemic lupus
erythematosus, scleroderma, thyroiditis, and multiple sclerosis. There are also implications of
autoimmune pathology in such common health problems as arteriosclerosis, inflammatory bowel
disease, schizophrenia, and certain types of infertility. Largely of unknown etiology, autoimmune
disorders affect approximately 3% of the North American and European populations, > 75% of
those affected being women. This discussion provides a brief introduction to the immune system
and tolerance maintenance, an overview of selected autoimmune diseases and possible
mechanisms of immune autoreactivity, and a review of experimental autoimmune models. Key
words: autoantibodies, autoimmune disease, autoimmunity, autoreactive immunity, immunity,
mechanisms, tolerance. - Environ Health Perspect 107(suppl 5):661-665 (1999).
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Autoimmune disorders result from a
breakdown ofimmunologic tolerance leading
to an immune response against self-mole-
cules. In most instances the events that initi-
ate the immune response to self-molecules
are unknown, but a number ofstudies sug-
gest associations with environmental and
genetic factors and certain types of infec-
tions. Approximately 3% ofthe populations
in Europe and North America currently suf-
fer from autoimmune diseases, many with
symptoms of multiple disorders (1). This
may be an underestimate, as epidemiologic
studies are not available for some ofthe less
common diseases. In addition, there are sug-
gestions that a number of common health
problems such as atherosclerosis and inflam-
matory bowel disease may have an autoim-
mune component (2,3). Women have a
significantly higher risk ofdeveloping an
autoimmune disease than men, as > 75% of
those suffering from autoimmune diseases
are female (1). Young, postpubescent women
have been shown to be approximately 10
times more susceptible than men to develop-
ing autoimmune disease (4). Although the
underlying mechanisms for this predisposi-
tion are currently being investigated, it is
known that females and castrated males pro-
duce much higher levels of estrogen and
reduced levels oftestosterone, and it is well
documented that estrogen and estrogenlike
chemicals may alter the immune response
(5). Much ofthe evidence supporting a role
for estrogen in the development of autoim-
mune diseases comes from animal models
rather than human studies. In autoimmune-
prone mice, estrogen administration greatly
enhances mortality in both males and
females (6). Testosterone is found in much
higher levels in sexually functionally males.
Recent studies have found that testosterone
given to lupus-prone autoimmune mice
exerts a powerful suppressive effect on this
disorder in both adult and prenatally treated
animals, and male autoimmune MRL/Ipr
mice exhibit abnormally low testosterone lev-
els (7). In this article, we provide a brief
introduction to a) the immune system; b) the
mechanisms bywhich tolerance to selfis nor-
mally maintained and the ways in which
these mechanisms may be broken down so
that autoreactivity can occur; c) an overview
ofautoimmune diseases and possible mecha-
nisms; and d) the models frequently used to
study the autoimmune phenomenon.
Overview ofthe Immune
System
The immune system is a complex set of
cellular, chemical, and soluble protein com-
ponents designed to protect the body
against foreign substances, including infec-
tious agents and tumor cells, while not
responding to self-molecules. Foreign or
self-molecules (usually proteins or carbohy-
drates) that evoke specific immune
responses are referred to as antigens.
Immune cells are located throughout the
body, either in discretely encapsulated
organs such as the spleen and thymus or as
diffuse accumulations of lymphoid and
myeloid cells as found in association with
the skin and gut where they are strategically
placed to monitor the entry offoreign sub-
stances. Optimal function of the immune
system requires that immune cells and cell
products interact with each other in a sequen-
tial, regulated manner. The distinction
between self and nonself occurs through
complex mechanisms that depend upon
specific recognition molecules present on
the surface of immunocompetent cells, in
particular, T and B lymphocytes.
Nonspecific effector mechanisms that
complement or amplify the specific T- and
B-lymphocyte responses are also important in
the immune response. These nonspecific enti-
ties serve as a first line of defense against
potential pathogens and include other leuko-
cytes such as macrophages, natural killer
(NK) cells, and polymorphonuclear leuko-
cytes, as well as soluble mediators that include
complement and cytokines. A number of
autoimmune diseases demonstrate character-
istic aberrations in cytokine production, sug-
gesting that these soluble mediators may play
a role in both the initiation and pathogenesis
ofthe disease (8-10). Therapeutic treatment
with the cytokines interferon (IFN)-a and
interleukin (IL)-2 have occasionally been
associated with the subsequent appearance of
autoimmune diseases (11). In addition to the
complex cell-cell and cytokine interactions
that are necessary in the normal functioning of
the immune system, secondary factors can
influence immune status. These include neuro-
hormones and stress, both ofwhich modulate
autoimmune responses (12).
Many immune cell populations (e.g.,
B lymphocytes, T lymphocytes, NK cells) can
be further divided into subpopulations on the
basis ofvarying functional properties or states
ofdifferentiation, maturation, and activation.
Most notable among these are the T-cell sub-
populations, including cells that assist and
amplify other immune responses (T-helper
cells [Th]), downregulate other immune
responses (T-suppressor [Ts] cells), or destroy
cells infected with viruses or other intracellu-
lar pathogens and tumor cells (cytotoxic T
[Tc] cells ). The Th cells produce cytokines
that regulate immune function and can be
further subdivided into subpopulations that
assist other T cells (Thl) or stimulate and
perpetuate antibody responses (Th2).
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Immunocompetent T cells develop and
mature in the thymus under the influence of
thymic hormones and peptides. T cells recog-
nize only antigens that have been processed
into peptide fragments and are presented as
bound to specialized cell-surface molecules,
the major histocompatibility complex
(MHC) proteins. MHC class I molecules are
expressed on nearly all nucleated cells ofthe
body. MHC class II molecules are constitu-
tively expressed on antigen-presenting cells
(APCs) only. However, class II expression can
be induced in a variety of cell types after
cytokine stimulation. The antigen recogni-
tion molecule for the T lymphocyte is the
T-cell receptor (TCR), a heterodimeric trans-
membrane molecule containing two subunits
(either (x3 or y6). The interaction between
antigen, the TCR, and MHC proteins is
highlycomplex, and T-cell activation requires
signaling via the TCR and other cell-surface
molecules.
Although B lymphocytes can act as APCs,
their primary role is to produce antibody,
which is the effector molecule for humoral-
mediated immunity. Naive, circulating B cells
encounter antigen in lymph nodes or tissue-
associated lymphoid tissues and become
activated. B cells recognize antigen via
membrane-bound antibody/immunoglobulin
(Ig) molecules that act as antigen receptors.
Cross-linking ofIg molecules on the cell sur-
face initiates a signal transduction cascade
and with the appropriate stimulus from Th2
cytokines, leads to activation and prolifera-
tion. These activated B cells clonally expand
by repeated division, followed by differentia-
tion into antibody-secreting plasma cells. The
reader should consult any one of several
excellent immunology texts for an extended
discussion ofthese interactions (13,14).
Tolerance
The genetics of the TCR and antibody
molecules are such that an incredible amount
of diversity is generated in the antigen-
binding portions ofthe molecule. As recom-
bination of Ig and TCR genes occurs in a
random manner, antigen-binding regions are
created that are reactive with self-molecules.
Thus a variety oftolerance mechanisms have
evolved to distinguish selfand nonself, and
block the development, growth, or differenti-
ation ofautoreactive lymphocytes. There are
three basic mechanisms by which self-reactive
lymphocytes may be prevented from respond-
ing to self-molecules: a) clonal deletion,
which requires the physical elimination of
autoreactive lymphocytes; b) clonal anergy,
which requires the functional elimination of
autoreactive lymphocytes via downregulation
ofresponsiveness, and c) suppression or inhi-
bition ofautoreactive lymphocytes via inter-
action with other cell types such as cytotoxic
T lymphocytes or NK cells. These cells
dampen the immune response to specific
antigens via secretion ofcytokines with nega-
tive regulatory effects, via antibody feedback
mechanisms that can neutralize specific anti-
gens and inhibit B-cell function through
cross-linking ofsurface Ig or Fc receptors, or
by the creation ofantiautoantibodies (anti-
idiotypes) that can recognize the antigen
receptor on autoreactive B lymphocytes (15).
It has been suggested that T lymphocytes
are the primary players in the initiation and
perpetuation of both spontaneous and
chemical-induced autoimmune diseases
(16,17). This is evidenced by animal mod-
els that demonstrate that autoimmunity can
be transferred via infusion of autoreactive
Th cell clones and that this transfer of
autoimmunity can be reversed by depletion
of the Th cell clones using antibodies and
complement (18-20).
T lymphocytes develop in the thymus
from hematopoietic stem cells that do not yet
express the cell-surface markers CD4 (Th
cells) or CD8 (Ts or Tc cells). These early
T-cell precursors randomly rearrange their
TCR genes and proliferate at a very high rate,
developing into a population ofCD4+CD8+
(double-positive) cells. In the cortical region
ofthe thymus, these double-positive T lym-
phocytes are exposed to epithelial cells that
express MHC class I and II molecules. T cells
that do not recognize self-MHC are deleted
via programmed cell death, whereas T cells
that bind to self-MHC molecules survive
(positive selection), differentiate into either
single-positive CD4 or CD8 cells (depending
on whether they bind MHC class II or class I,
respectively), and migrate into the medulla of
the thymus. In the medulla, single-positive
cells are exposed to autoantigens in the pres-
ence ofself-MHC molecules. Those T cells
that bind self-antigens with high affinity are
deleted (negative selection) viaTCR-mediated
programmed cell death. Autoreactive T
lymphocytes that are not deleted in the
thymus (due to low affinity binding or
responsiveness to cryptic antigens, i.e., self-
antigens not present in the thymus during
normal development) are usually anergized or
suppressed in the peripheral lymphoid tissues.
The simplest mechanism to explain
tolerance in B lymphocytes is a lack ofT-cell
help for self-reactive B cells as a result ofsuc-
cessful T-cell tolerance (21). However, some
B cells must be directly tolerized. A number
ofmicroorganisms express molecules resem-
bling self-antigens (molecular mimicry).
Furthermore, Ig genes in mature B cells may
undergo somatic mutation during clonal
expansion so that they become self-reactive.
The fate ofself-reactive B cells depends on
the affinity ofthe Ig receptor for its specific
antigen and on the nature ofthe antigen it
encounters. When B cells encounter
membrane-associated self-antigens that cross-
link surface Ig receptors with high aviditiy,
their surface Ig is downregulated and these
short-lived cells die via apoptosis. This type of
tolerance occurs most frequently in the bone
marrow. However, some self-reactive B cells
reach the periphery. Ifthese cells encounter
soluble antigen that is monomeric and not
capable ofcross-linking surface Ig receptors,
they are rendered anergic via downregulation
ofsurface IgM. This anergy may be reversible
in the presence of high levels of the cell-
surface antigen CD40 and IL-4 or polyclonal
activators such as lipopolysaccharide and
mycoplasma superantigen (22).
Overview ofAutoimmune
Diseases
Autoimmune disorders are a spectrum of
diseases ranging from organ specific, in which
antibodies and T cells react to self-antigens
localized in a specific tissue, to systemic,
which are characterized by reactivity against a
specific antigen or antigens spread throughout
various tissues in the body (Table 1). In
Table 1. Spectrum of autoimmune diseases and putative autoantigens.
Disease
Organ specific
Non-organ specific
Hashimoto thyroiditis
Thyrotoxicosis
Pernicious anemia
Autoimmune atropic gastritis
Addison disease
Insulin-dependent diabetes mellitus
Goodpasture syndrome
Myasthenia gravis
Male infertility Ifew cases)
Sympathetic opthalmia
Multiple sclerosis
Autoimmune hemolytic anemia
Ulcerative colitis
Rheumatoid arthritis
Scleroderma
Systemic lupus erythematosus
Autoantigen
Thyroglobulin
Thyroid-stimulating hormone
H+/K+ -ATPase
Intrinsic factor
21-Hydroxylase
Glutamic acid decarboxylase 65
Type IVcollagen
Acetylcholine receptor
Epididymal glycoprotein FA-1
Interphotoreceptor retinol binding protein
Myelin basic protein
X antigen, glycophorin
Catalase, a-enolase
Rheumatoid factor
Topoisomerase 1, laminins
DNA nucleotides and histones, Sm-RNP
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general, ThI cytokines such as IL-2 and
IFN-y predominate in organ-specific dis-
eases, and the effector responses tend to
occur via cell-mediated immune responses
such as killing by cytotoxic T cells through
the release ofcytokines or through IgG and
IgM antibodies directed toward cell-surface
antigens, triggering Fc receptor-mediated
killing. Systemic autoimmune disorders are
characterized by elevated levels of Th2
cytokines such as IL-4, IL-5, and IL-10, the
widespread circulation ofautoantibodies and
immune complex deposition, opsonization
with antibody, and cell damage via comple-
ment-mediated lysis. Some autoimmune syn-
dromes such as multiple sclerosis are not
easily classified, as they demonstrate both
organ-specific and systemic components.
The most common targets for organ-specific
autoimmune disease are the thyroid
(Hashimoto thyroiditis, thyrotoxicosis),
stomach (pernicious anemia, autoimmune
atrophic gastritis), adrenal glands (Addison
disease), and pancreas (type I or insulin-
dependent diabetes mellitus [IDDM]).
Systemic autoimmune disorders commonly
involve the skin (scleroderma), the joints
(rheumatoid arthritis), and the muscle tissue
(idiopathic inflammatory myopathies [IIM]).
In many instances multiple autoimmune dis-
eases may occur in the same patient, and cer-
tain diseases are sometimes associated, such as
IIM and vasculitis or rheumatoid arthritis and
systemiclupus erythematosus (SLE) (23-25).
In recent years it has been recognized
that many other diseases in a variety of
target organs/tissues may have an autoim-
mune component. In general, the etiology of
these diseases is not well understood, and
multiple factors such as genetics, infectious
agents, and lifestyle may contribute in some
fashion to disease induction and progres-
sion. There is significant evidence that an
immune response to self-antigens is involved
in atherosclerosis. Increased levels ofautoan-
tibodies to heat shock protein 65/60, gan-
gliosides, and oxidized low-density
lipoproteins have been demonstrated in ath-
erosclerotic lesions (26-28). The role of
heat shock protein 65/60 as a candidate
autoantigen is supported by animal studies
in which immunization with this antigen led
to the development ofatheroslcerotic lesions
in rabbit aorta (29). In addition, elevated
levels of MHC class II expression and
increased production ofgrowth-promoting
and chemotactic cytokines have been shown
in atherosclerotic plaques (30,31). There is
also evidence for an autoimmune pathology
in schizophrenia, with immunologic abnor-
malities, such as increased prevalence of
antinuclear and platelet-associated antibod-
ies, altered cytokine production, and
increased levels ofsoluble cytokine receptors
being reported (32,33). Abnormal antibody
production and autoimmunity have also
been implicated in both male and female
infertility and are associated with recurrent
spontaneous abortion, endometriosis, prema-
ture ovarian failure, and abnormal sperm
maturation (34,35).
Mechanisms ofAutoimmune
Disease
A small number ofautoreactive B and T cells
constitute a normal part ofthe immune cell
pool, as the production ofautoantibodies is
frequently observed in normal healthy indi-
viduals. Tolerance is normally maintained by
the regulatory interactions ofa variety ofcell
types and soluble mediators. However, under
certain conditions, tolerance can be broken
and an autoimmune pathology may result. It
is apparent that development ofautoimmune
disease is highly dependent on a permissive
genetic background but that other triggering
factors such as viral, bacterial, or chemical
insult lead to altered self-reactivity. This sec-
tion is meant to introduce the reader to sev-
eral ofthe hypotheses regarding the role that
genetics and environmental factors may play
in breaking down the barrier to reactivity
with self-antigens.
Release ofIsolatedAutoantugens
T cells reactive to self-antigens not present in
the thymus during the early stages ofT-cell
development may escape thymic deletion.
These antigens (cryptic or hidden antigens)
generally have relatively low circulating levels
or are anatomically sequestered in specific tis-
sues (e.g., myelin basic protein or thyroglob-
ulin) where vascular and/or cellular basement
membranes constitute an effective barrier
that prevents access by autoreactive cells.
Induction oforgan-specific autoimmune dis-
ease following tissue trauma has been fre-
quently reported and likely occurs via tissue
damage that results in the availability ofpre-
viously isolated antigens, as is the case in
ophthalmia following eye injury (36) or
orchiditis following vasectomy (37,38).
Infection with tissue-tropic pathogens such
as viruses may induce similar autoimmune
phenomenon, and these infections also pro-
vide the additional stimulus ofthe produc-
tion ofsoluble mediators and costimulatory
molecules important in the perpetuation of
the immune response. This may be best
exemplified in rodents and humans who
develop diabetes after infection with
Coxsackie B viruses (39).
ChemicalAlteration ofSelf-Peptides
As discussed above, T lymphocytes that bind
with low affinity to self-proteins in the thy-
mus may not be deleted. However, these
T cells are normally functionally anergized in
the periphery. Responses to and presentation
ofthese cryptic self-peptides can be enhanced
under certain conditions. In a murine model
ofIDDM, viral infection stimulates the secre-
tion ofIFN-y, which in turn upregulates lev-
els of antigen-presenting MHC molecules
and enhances presentation oflow-affinityself-
peptides (40). Some metals induce auto-
immune disease via the creation of new
high-affinity binding sites for MHC mole-
cules on chemical-bound self-peptides, allow-
ing activation ofpreviously anergized T cells
(41). Expression ofaltered nucleolar proteins
appears to be an important step in the devel-
opment of mercuric chloride (HgCI2)-
induced autoimmunity in a rodent model of
SLE (42). In addition, many drugs induce
autoimmunity via formation of hapten-
induced autoantibodies. Compounds such as
penicillin and halothane induce reactions in
which hapten-specific T cells provide help to
antibody-producing B cells that recognize the
modified hapten but not the native form of
theself-protein (43-45).
MolecularMimicry
Many peptide fragments ofinfectious agents
are homologous with host proteins and induce
organ-specific autoimmune responses. A mem-
brane protein on the P-hemolytic streptococ-
cus bacterium has a high degree ofhomology
with cardiac myosin, andantibodies that target
the bacterium also cross-react with cardiac
muscle and induce rheumatic fever (46,47).
Yersinia enterocolitica, a bacterium normally
associated with food poisoning outbreaks, has
also been associated with various autoimmune
diseases. Increased levels ofantibodies to
Yersinia have been demonstrated in patients
with Graves disease or autoimmune thyroiditis
(48,49). These antibodies cross-react with a
varietyofthyroid antigens (50,51).
Polycoia Acivators
Microbial antigens have also been implicated
in the precipitation and exacerbation ofsys-
temic autoimmune diseases. Exogenous
polyclonal activators may mutually stimulate
T cells that react with both MHC class II-
bound superantigens (peptides that activate
large numbers of Th cells, promoting
cytokine overproduction) on B cells and the
B cells themselves, leading to the production
of polyclonal Ig, some of which may be
autoreactive (52). Mycoplasma arthriditis
superantigen stimulates cytokine production
and upregulates MHC class II expression in
human T cell lines (53) and stimulates
T lymphocytes with arthritis-associated
TCR-P chains (54). In a rodent model,
Mycoplasma arthriditis superantigen stimu-
lated Th cells, resulting in polyclonal B-cell
activation and/or differentiation ofantigen-
specific B cells (55).
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GeneticFactors
Familial studies suggest a clear association
between genetics and autoimmune diseases,
particularly those with an organ-specific
pathology (56). Further, although concor-
dance rates between identical twins can be
relatively low depending on the disease, this
may be explained by nonidentity in immune
repertoires because ofTCR and Ig gene
recombination, variations in receptor assem-
bly, and somatic mutation ofB-cell receptors.
The most clearly established genetic associa-
tion is with specific alleles within the MHC
gene complex. Certain haplotypes (HLA-B8,
DR2-DR5) tend to be associated with certain
autoimmune diseases [reviewed in (57,58)].
However, a specific MHC haplotype is not
sufficient for development ofautoimmune
disease, and autoimmunity-associated haplo-
types are found in individuals with no clinical
signs ofdisease.
There are also a number of non-MHC
genes that may contribute to autoimmunity.
Many studies have examined the possibility
that predisposition for certain autoimmune
diseases in the human population may lie in
the germline genes for the TCR [reviewed in
(59,60)]. The strongest evidence for TCR
involvement comes from studies ofsibling
pairs with recurrent/relapsing multiple scle-
rosis. Siblings with multiple sclerosis shared
specific TCR-j3 haplotypes at a frequency
much higher than would be expected
because ofrandom segregation (61). TCR-ax
gene polymorphisms have also been
associated with disease susceptibility (62).
Animal Models of
Autoimmune Disease
Three basic types ofanimal models may be
employed to identify the potential ofenvi-
ronmental agents to induce autoimmune
responses: a) organic- or chemical-induced,
b) autoimmunization, or c) genetically pre-
disposed animals (Table 2).
In models where autoimmunity is induced
byexposure to chemical orbiologicagents, for-
eign substances are used to initiate the
autoimmune disease state. These may indude
chemicals, drugs, or biologic substances such
as bacterial or viral antigens. One ofthe more
commonly employed models ofthis type is
the Brown Norway rat model, in which the
animals are injected with nontoxic amounts of
HgCl2. The chemical exposure produces no
overt signs oftoxicity, yet the rats develop an
immunologically mediated disease character-
ized by T-cell-dependent polyclonal B-cell
activation, autoantibodies to laminin, collagen
IV and other components ofthe glomerular
basement membrane, and nephrotic syn-
drome with proteinuria similar to that
observed in humans with autoimmune
glomerulonephritis (63).
Autoimmunization with purified self-
antigens can elicit a specific autoimmune
response, particularly when adjuvants are
administered in conjunction with self-
proteins. A frequently used model of this
type-experimental autoimmune encephalo-
myelitis-is induced by immunization of
rodents with myelin basic protein with
Table 2. Experimental models forautoimmune diseases.a
Classification
Organic orchemical Genetically pre- Autoimmune disease induction Autoimmunization disposed strains
Autoimmune thyroiditis Thyroglobulin - experimental MRL(m)
autoimmune thyroiditis (m,r) BB(r)
OS (ch)
Insulin-dependent Streptozotocin (m) NOD (m)
diabetes mellitus BB(r)
DRBB (r)
BN (r)
Myasthenia gravis Penicillamine (m,r) Acetylcholine receptor-
experimental autoimmune
myasthenia gravis (m,r)
Multiple sclerosis Myelin basic protein -
experimental autoimmune
encephalomyelitis (m,r,ch)
Rheumatoid arthritis Streptococcal cell wall (r) CFA+ type 11 collagen (m,r,mo) MRL/Ipr(m)
CFA+ mycobacterium heat SCID (m)
shock protein (m,r) HLA B27 (r) Systemic lupus Mercury (m,r,mo) CFA +anti-DNA antibodies (m,r) MRL+/+(m)
erythematosus Penicillamine (m,r) MRL/Ipr(m)
Procainamide (m,r) MRL-mp-lpr/lpr(m)
NZW2410(m)
NZB/NZW(m) Systemic sclerosis TSK(m) (scleroderma)
Abbreviations: CFA, complete Freund's adjuvant; chicken, ch; m, mouse; mo, monkey; r, rat.'Table adapted from Lo (65), Bigazzi (67), and Cohen and Miller(68).
Freund's complete adjuvant. The resulting
pathology is a Th-cell-mediated auto-
immune disease characterized by central ner-
vous system perivascular lymphocyte
infiltration and destruction of the myelin
nerve sheath with resultant paralysis similar
to that observed in patients with multiple
sclerosis (64).
The genetically predisposed models,
whether naturally occurring, transgenic, or
knockout based, tend to be the most reliable
and therefore have been more commonly
employed in autoimmunity research (65). In
these models, mild to severe syndromes spon-
taneously develop, usually because ofspecific
MHC allele mutations encoding class II mol-
ecules and often inducing functional abnor-
malities oftheTh cell (66).
In each type ofmodel the development
and severity ofsymptoms have multiple com-
ponents in that the presence ofthe disease
and its progression can be influenced by age,
hormonal, and/or environmental factors. In
addition, there is a tendency for more than
one autoimmune disorder to occur in several
of the individual models. Nevertheless, a
number ofsyndromes similar to those clini-
cally observed in humans can be mimicked in
animal models.
Summary
Many questions remain with respect to the
specific etiology ofa majority ofthe autoim-
mune disorders. The exact nature ofthe incit-
ing antigen, the regulatory mechanisms that
govern the onset and extent of the auto-
immune response, the mechanisms by which
spontaneous remissions and flare-ups occur,
the role ofenvironmental factors and how
they initiate and perpetuate autoimmune
responses, and the identity and mechanism of
action ofgenes that predispose or accelerate
autoimmunity continue to elude scientists in
the field. These critical issues will be the focus
offuture research efforts.
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